Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer

BACKGROUND: The updated randomised phase 2/3 FIRIS study demonstrated the noninferiority of IRIS (irinotecan and S-1) to FOLFIRI (irinotecan, folinic acid, and 5-FU) for metastatic colorectal cancer. Meanwhile, in the subset analysis including patients who previously have undergone oxaliplatin-conta...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, H, Watanabe, M, Okabe, H, Miyamoto, Y, Sakamoto, Y, Baba, Y, Iwatsuki, M, Chikamoto, A, Beppu, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516688/
https://www.ncbi.nlm.nih.gov/pubmed/23169295
http://dx.doi.org/10.1038/bjc.2012.502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516688/
https://www.ncbi.nlm.nih.gov/pubmed/23169295
http://dx.doi.org/10.1038/bjc.2012.502

Ejemplares similares